Contact
searchSearch
HMP Global
Login

Endometrial Cancer Specialty Channel

Endometrial Cancer
Specialty Channel
Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology
News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology
Quiz
Adjuvant Chemotherapy Plus Radiation for Patients With High-Risk Endometrial Cancer
11/26/2024
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year...
11/26/2024
Oncology
Quiz
Intraoperative Radiation Therapy for Patients With Recurrent Cervical or Endometrial Cancer
11/26/2024
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation...
11/26/2024
Oncology
News
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
11/19/2024
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer
11/19/2024
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized...
11/19/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology

News

News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology
News
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
11/19/2024
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer
11/19/2024
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized...
11/19/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
News
Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer
08/29/2024
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a...
08/29/2024
Oncology
News
No Difference in Survival Between Minimally Invasive and Open Staging Surgeries for Patients With Non-Endometrioid Endometrial Cancer
08/20/2024
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found...
08/20/2024
Oncology

Interactive Features

Quiz
Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology
Quiz
Adjuvant Chemotherapy Plus Radiation for Patients With High-Risk Endometrial Cancer
11/26/2024
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?
Do you know what the 5-year...
11/26/2024
Oncology
Quiz
Intraoperative Radiation Therapy for Patients With Recurrent Cervical or Endometrial Cancer
11/26/2024
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation therapy a feasible and safe option for certain patients with recurrent or persistent cervical or endometrial cancer?
Is intraoperative radiation...
11/26/2024
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
Response to Datopotamab Deruxtecan Among Patients With Endometrial Cancer
09/30/2024
In the TROPION-PanTumor03 study, what was the confirmed objective response rate among patients with endometrial cancer treated with datopotamab deruxtecan?
In the TROPION-PanTumor03 study, what was the confirmed objective response rate among patients with endometrial cancer treated with datopotamab deruxtecan?
In the TROPION-PanTumor03 study,...
09/30/2024
Oncology
Quiz
Correlation Between Lymph Node Dissection at Hysterectomy and Survival in Patients With Endometrial Cancer
09/30/2024
According to results from a univariable and multivariable analysis, does lymph node dissection at the time of hysterectomy improve overall survival among patients with stage 3 endometrial cancer?
According to results from a univariable and multivariable analysis, does lymph node dissection at the time of hysterectomy improve overall survival among patients with stage 3 endometrial cancer?
According to results from a...
09/30/2024
Oncology
Quiz
Well-Being and Quality of Life in Endometrial Cancer
08/28/2024
Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.
Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.
Do you know which factors can...
08/28/2024
Oncology
Quiz
Sacituzumab Govitecan for Patients With Heavily Pretreated Advanced or Metastatic Endometrial Cancer
08/28/2024
Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.
Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.
Do you know whether sacituzumab...
08/28/2024
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology

Recent News

News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology
News
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
11/19/2024
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer
11/19/2024
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized...
11/19/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
News
Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer
08/29/2024
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
According to results from a...
08/29/2024
Oncology
News
No Difference in Survival Between Minimally Invasive and Open Staging Surgeries for Patients With Non-Endometrioid Endometrial Cancer
08/20/2024
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found for progression-free survival, overall survival, or surgical complications between minimally invasive or open staging surgeries among patients with non-endometrioid endometrial cancer.
There were no differences found...
08/20/2024
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use